http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 24 Aug 2026 17:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Theriva+Biologics%2C+Inc.++++++++++++++/26968982.html si-local-file:///var/storage/secattach/20260824/26968982.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Theriva+Biologics%2C+Inc.++++++++++++++/26968982.html Mon, 24 Aug 2026 17:01:00 -0400 O.03089849 TOVX http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Theriva+Biologics%2C+Inc.++++++++++++++/26968982.html si-local-file:///var/storage/secattach/20260824/26968982.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Theriva+Biologics%2C+Inc.++++++++++++++/26968982.html Mon, 24 Aug 2026 17:01:00 -0400 O.03089849 TOVX http://www.streetinsider.com/Earnings/Theriva+Biologics+%28TOVX%29+Misses+Q2+EPS+by+1c/26902997.html <p>Theriva Biologics (NYSE: TOVX) reported Q2 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06).</p><p>For earnings history and earnings-related data on Theriva Biologics (TOVX) <a href="http://www.streetinsider.com/ec_earnings.php?q=TOVX">click here</a>.</p> http://www.streetinsider.com/Earnings/Theriva+Biologics+%28TOVX%29+Misses+Q2+EPS+by+1c/26902997.html Tue, 11 Aug 2026 09:39:40 -0400 TOVX http://www.streetinsider.com/Earnings/Theriva+Biologics+%28TOVX%29+Misses+Q2+EPS+by+1c/26902996.html <p>Theriva Biologics (NYSE: TOVX) reported Q2 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06).</p><p>For earnings history and earnings-related data on Theriva Biologics (TOVX) <a href="http://www.streetinsider.com/ec_earnings.php?q=TOVX">click here</a>.</p> http://www.streetinsider.com/Earnings/Theriva+Biologics+%28TOVX%29+Misses+Q2+EPS+by+1c/26902996.html Tue, 11 Aug 2026 09:39:39 -0400 TOVX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Theriva+Biologics%2C+Inc.+++For%3A+Jun+30/26901972.html si-local-file:///var/storage/secattach/20260811/26901972.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Theriva+Biologics%2C+Inc.+++For%3A+Jun+30/26901972.html Tue, 11 Aug 2026 08:16:00 -0400 O.03089849 TOVX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Theriva+Biologics%2C+Inc.+++For%3A+Jun+30/26901972.html si-local-file:///var/storage/secattach/20260811/26901972.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Theriva+Biologics%2C+Inc.+++For%3A+Jun+30/26901972.html Tue, 11 Aug 2026 08:16:00 -0400 O.03089849 TOVX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Theriva+Biologics%2C+Inc.+++For%3A+Aug+11/26901939.html si-local-file:///var/storage/secattach/20260811/26901939.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Theriva+Biologics%2C+Inc.+++For%3A+Aug+11/26901939.html Tue, 11 Aug 2026 08:10:00 -0400 O.03089849 TOVX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Theriva+Biologics%2C+Inc.+++For%3A+Aug+11/26901939.html si-local-file:///var/storage/secattach/20260811/26901939.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Theriva+Biologics%2C+Inc.+++For%3A+Aug+11/26901939.html Tue, 11 Aug 2026 08:10:00 -0400 O.03089849 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Press+Releases/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html <p align="center">– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients –</p> <p align="center">– Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1 2027 –</p> <p align="left">ROCKVILLE, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results http://www.streetinsider.com/Globe+Newswire/Theriva%E2%84%A2+Biologics+Reports+Second+Quarter+2026+Operational+Highlights+and+Financial+Results/26901792.html Tue, 11 Aug 2026 08:00:00 -0400 A.06822034 A.31066700 A.34398696 O.00178204 O.03089849 O.20026344 O.22422661 TOVX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Theriva+Biologics%2C+Inc.+++For%3A+Aug+06/26879461.html si-local-file:///var/storage/secattach/20260806/26879461.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Theriva+Biologics%2C+Inc.+++For%3A+Aug+06/26879461.html Thu, 06 Aug 2026 08:11:00 -0400 O.03089849 TOVX